secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2023-05-25T23:59:59+00:00
Accession:  0001193125-23-154191
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KPTI shareholders approve doubling authorized shares to 400M, equity plan increases
--------------------------------------------------------------------------------

- Authorized shares doubled from 200M to 400M after shareholder approval at the May 24, 2023 annual meeting.
- Stockholders approved adding 5M new shares to the 2022 Equity Incentive Plan for future awards.
- Amended ESPP increases share reserve from ~2.5M to ~4M and removes the evergreen provision.
- Officer exculpation amendment approved, limiting officer liability for certain breach of fiduciary duty claims.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000119312523154191/0001193125-23-154191-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000119312523154191/d512308d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-154191

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer